Moujaro, built by Ellie Lily and the company’s packaging, has been seen in a pharmacy photo taken in a pharmacy in Cracko, Poland on 9 April 2024.
Nurphoto | Nurphoto | Getty images
Ellie lily On Thursday, it said that its blockbuster diabetes drug Maunzaro showed heart health benefits in late phase testing, which directly compare the company’s old diabetes treatment, trulicity.
Mounjaro met the main goal of the study to show the main goal of showing that it was not worse than being stricken in the treatment of type 2 diabetes and established heart disease. Elli Lily said that it believes that new data saw the case as the first choice for patients with type 2 diabetes, who are, who are, There is a possibility of heart disease or stroke twice As those people without disease.
Results come as trulicity. A top-bound drug for Elie Lily also faces a patent termination in 2027, which can further promote the position of Maunjaro in the diabetes market.
Mounjaro met the main goal of a five -year study, causing type 2 diabetes and heart disease with heart death, heart attack, heart attack or stroke to 8%, compared to adults. But Ellie Lily’s shares fell nearly 2% in premarket trading on Thursday, as those consequences considered the benchmark of some analysts better than trulicity.
Nevertheless, the company stated that Maunzaro showed additional, “more comprehensive” benefits on trinulis in the test, including 16% lower rate of death and higher renal protection for any reason. It was the longest and largest test on Tirzepatide, active in Mounjaro, enrolling more than 13,000 people.
Some physicians stated that the results, especially the low risk of heart events, are not surprising, as they believed that silence would be able to provide heart benefits.
But the difference in the rate of death between Maunjaro and trulicity is “really deep” and “certainly something clinically meaningful for us,” Dr. David Broom said, the clinical assistant professor in the Department of Metabolism, Endocrinology and Diabetes of Michigan University.
He said that the data helped determine the difference between Maunjaro and trulicity, which would help the providers and patients to determine the best treatment to move forward in their shared decisions. Broom said that the decision -making people between patients and providers would eventually depend on several factors, such as their insurance coverage, the side effects of a given drug and how well the patient tolerates them.
Dr. Howard Ventrab, Clinical Director of the Center for the Prevention of Cardiovascular Disease at NYU Langon Heart, Munjaro is called the “winner” in the trial, which only comes from the negative side, which has a slightly more side effects than the trulicity. But he said that the results cannot motivate more people to start silence, and that the high list of drugs can prevent the value insurers from covering it if it is not much better than the trulis.
Wentrabing said that he hopes when full results are presented in a European medical meeting and a colleague reviewed in the fall, published in a magazine, a lot of “dig” in the data.
Elli Lily saw the results of the test as an indicator that physicians should select Maunjaro for the patient group.
“This strengthens the overall story. In my mind, it raises the question, ‘Why won’t you choose Mounjaro?” “Lily cardiometabolic health president Kane Caster said in an interview.
The result “removes any doubt as to why it is the right medicine for a patient with type 2 diabetes and type 2 diabetes with heart risk,” he said, saying that it is “difficult for patients to say” it is difficult for patients to cover this medicine. “
Results also come because Elli Lily has strengthened her leadership Novo nordisk In the rapidly growing market for weight loss and diabetic drugs. The study of the two companies has shown additional health benefits of its medicines for conditions such as obstructive sleep apnea and chronic kidney disease.
Elli Lily plans to present heart health data to global regulators by the end of the year, and the company said that for this purpose in 2026 for this purpose – and expansion insurance coverage – by expansion insurance coverage.
Is the company Currently studying Heart benefits of zepbound in obesity and installed heart disease patients. According to Eli Lily’s website, phase three tests are expected to be wrapped in 2027.
Even if regulatory type 2 approves mounjaro for the treatment of heart disease in patients with diabetes, it cannot greatly expand the use of the drug. This is because the current approval of the mounjaro for type 2 diabetes already covers many of those patients: around 30% people with type 2 diabetes According to the Heart Foundation, there is also heart disease.
Further in the June 1 research note of the data, TD Cowen analyst Steve Skala stated that he believes that the uplift of tirzeptide will “be very unaffected” if it shows the same heart health benefits as a triple.
Lerink Partners’ analyst David Reginger said in a separate note in June, “Tirzepatide is already receiving” significant adoption “in the market due to” strong profile “. He said the experts agreed that the heart benefits of the Tirzepetide were better or matched those quarterly in the study, the results “would not change the decisions of doctors”.
Maunzaro showed a greater improvement than trulicity when it came to reduce some heart remedies and body weight and A1C, a measure of blood sugar levels.
The safety data of both Mounjaro and Trulicity were generally in line with seen in the past. The most reported adverse events for both drugs were related to the gastrointestinal and typically lightened to moderate.
– CNBC Angelica Pables Contributed to this report.
